211 related articles for article (PubMed ID: 25197055)
1. Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.
Robert F; Roman W; Bramoullé A; Fellmann C; Roulston A; Shustik C; Porco JA; Shore GC; Sebag M; Pelletier J
Proc Natl Acad Sci U S A; 2014 Sep; 111(37):13421-6. PubMed ID: 25197055
[TBL] [Abstract][Full Text] [Related]
2. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis.
Lin CJ; Nasr Z; Premsrirut PK; Porco JA; Hippo Y; Lowe SW; Pelletier J
Cell Rep; 2012 Apr; 1(4):325-33. PubMed ID: 22573234
[TBL] [Abstract][Full Text] [Related]
3. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
4. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
5. Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.
Oblinger JL; Burns SS; Akhmametyeva EM; Huang J; Pan L; Ren Y; Shen R; Miles-Markley B; Moberly AC; Kinghorn AD; Welling DB; Chang LS
Neuro Oncol; 2016 Sep; 18(9):1265-77. PubMed ID: 26951381
[TBL] [Abstract][Full Text] [Related]
6. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A.
Cencic R; Robert F; Galicia-Vázquez G; Malina A; Ravindar K; Somaiah R; Pierre P; Tanaka J; Deslongchamps P; Pelletier J
Blood Cancer J; 2013 Jul; 3(7):e128. PubMed ID: 23872707
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation.
Rubio CA; Weisburd B; Holderfield M; Arias C; Fang E; DeRisi JL; Fanidi A
Genome Biol; 2014; 15(10):476. PubMed ID: 25273840
[TBL] [Abstract][Full Text] [Related]
9. The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction.
Descamps G; Gomez-Bougie P; Tamburini J; Green A; Bouscary D; Maïga S; Moreau P; Le Gouill S; Pellat-Deceunynck C; Amiot M
Br J Cancer; 2012 May; 106(10):1660-7. PubMed ID: 22510748
[TBL] [Abstract][Full Text] [Related]
10. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun SY
Neoplasia; 2010 Oct; 12(10):848-55. PubMed ID: 20927323
[TBL] [Abstract][Full Text] [Related]
11. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
Wu Y; Wang H
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
[TBL] [Abstract][Full Text] [Related]
12. eIF4F: a retrospective.
Merrick WC
J Biol Chem; 2015 Oct; 290(40):24091-9. PubMed ID: 26324716
[TBL] [Abstract][Full Text] [Related]
13. Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.
Issaenko OA; Bitterman PB; Polunovsky VA; Dahlberg PS
Cancer Gene Ther; 2012 Sep; 19(9):609-18. PubMed ID: 22767218
[TBL] [Abstract][Full Text] [Related]
14. Requirement of the eukaryotic translation initiation factor 4F complex in hepatitis E virus replication.
Zhou X; Xu L; Wang Y; Wang W; Sprengers D; Metselaar HJ; Peppelenbosch MP; Pan Q
Antiviral Res; 2015 Dec; 124():11-9. PubMed ID: 26526587
[TBL] [Abstract][Full Text] [Related]
15. Targeting the eIF4F translation initiation complex for cancer therapy.
Konicek BW; Dumstorf CA; Graff JR
Cell Cycle; 2008 Aug; 7(16):2466-71. PubMed ID: 18719377
[TBL] [Abstract][Full Text] [Related]
16. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.
Pelletier J; Graff J; Ruggero D; Sonenberg N
Cancer Res; 2015 Jan; 75(2):250-63. PubMed ID: 25593033
[TBL] [Abstract][Full Text] [Related]
17. RNA-tethering assay and eIF4G:eIF4A obligate dimer design uncovers multiple eIF4F functional complexes.
Robert F; Cencic R; Cai R; Schmeing TM; Pelletier J
Nucleic Acids Res; 2020 Sep; 48(15):8562-8575. PubMed ID: 32749456
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic initiation factor (eIF) 4F binding to barley yellow dwarf virus (BYDV) 3'-untranslated region correlates with translation efficiency.
Banerjee B; Goss DJ
J Biol Chem; 2014 Feb; 289(7):4286-94. PubMed ID: 24379412
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of small molecules targeting eIF4A.
Naineni SK; Itoua Maïga R; Cencic R; Putnam AA; Amador LA; Rodriguez AD; Jankowsky E; Pelletier J
RNA; 2020 May; 26(5):541-549. PubMed ID: 32014999
[TBL] [Abstract][Full Text] [Related]
20. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.
Lin CJ; Cencic R; Mills JR; Robert F; Pelletier J
Cancer Res; 2008 Jul; 68(13):5326-34. PubMed ID: 18593934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
